Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have instigated a paradigm shift in the management of cardiometabolic disease. Initially developed for glycemic control in type 2 diabetes, their therapeutic role has expanded dramatically following the demon-stration of robust cardiovascular benefits in large-scale clinical trials. This review provides a comprehensive synthesis of the physiological mechanisms underlying the cardiopro-tective effects of GLP-1 RAs, moving beyond the clinical outcomes to explore the cellular and molecular pathways involved. We systematically deconstruct the effects of this drug class on the vasculature, where they mitigate atherosclerosis by improving endothelial function, attenuating vascular inflammation and oxidative stress, and favorably modu-lating plaque composition. We then delve into the complex and controversial effects on the myocardium, addressing the debate over GLP-1 receptor expression and detailing the interplay of direct and indirect actions on cardiomyocyte metabolism, ion homeostasis, and fibrosis. A central focus is the differential impact of GLP-1 RAs on heart failure (HF) phenotypes, clarifying their established benefits in HF with preserved ejection fraction (HFpEF)—largely through targeting obesity and inflammation—and their neutrality or potential for harm in HF with reduced ejection fraction (HFrEF). By integrating evidence from landmark trials with cutting-edge mechanistic studies, this review illuminates how GLP-1 RAs exert their profound cardiovascular effects and identifies critical unanswered questions that will shape the future of cardiometabolic medicine.
Masab Mansoor (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: